Log In
Print this Print this

Zafatek, trelagliptin (SYR-472)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionOnce weekly oral formulation of dipeptidyl peptidase-4 (DPP-4) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation Japan - Standard Review (Treat Type II diabetes)
PartnerAllergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today